Regeneron Pharmaceuticals said Wednesday that President Donald Trump’s experimental treatment of coronavirus antibody mixtures in a trial of nearly 800 patients with mild to moderate Covid-19 has greatly reduced the number of visits.
Regeneron said that in 29 days, patients treated with REGN-COV2 decreased by about 57% in patients receiving Covid-19-related medical visits compared with patients receiving placebo.
For patients with one or more risk factors, such as those over the age of 50, obesity, cardiovascular, metabolic, lung, liver or kidney disease, or immunocompromised patients, this decrease is about 72%.
Last month, the company released early data from the trial, which showed that the treatment lowered the virus levels and improved symptoms of Covid-1
Regeneron’s drug is a mixture of two monoclonal antibodies-an artificial replica of an antibody, and is one of the main weapons of the immune system against infection.
Trump has attributed the Regeneron therapy to the recovery from Covid-19 and said he will promote emergency use authorization for the therapy and other similar drugs. He also said that he hopes to provide it to Americans for free.
The company applied for an emergency use authorization for dual antibody therapy with the U.S. Food and Drug Administration (FDA) earlier this month. The company said it has shared new data with regulators as part of a review of its requirements.
Eli Lilly and Co. manufactures similar drugs and has applied for EUA. The company signed a $375 million contract on Wednesday to provide 300,000 doses of therapeutic drugs to the US government.
Regeneron said earlier this month that it is ready to distribute about 50,000 doses of therapeutic drugs.
The federal government agreed in June to purchase up to 300,000 doses of the antibody mixture for $450 million.